Evidence map›Paper›PMID 21203426›Full record

ArticlePloS one2010

Targeted amino-terminal acetylation of recombinant proteins in E. coli.

Matthew Johnson, Arthur T Coulton, Michael A Geeves, Daniel P Mulvihill

Abstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The disordered and structured regions ofbioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Amyloid formation of alternatively spliced variants of α-synuclein.Protein science : a publication of the Protein Society · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Binding adaptability of chemical ligands to polymorphic α-synuclein amyloid fibrils.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matthew JohnsonSchool of Biosciences, University of Kent, Canterbury, United Kingdom.
Arthur T Coulton
Michael A Geeves
Daniel P Mulvihill

Funding

Biotechnology and Biological Sciences Research Council BB/F011784/1Biotechnology and Biological Sciences Research Council JF20605Wellcome Trust 085309
6 · The paper itself

Abstract

One major limitation in the expression of eukaryotic proteins in bacteria is an inability to post-translationally modify the expressed protein. Amino-terminal acetylation is one such modification that can be essential for protein function. By co-expressing the fission yeast NatB complex with the target protein in E.coli, we report a simple and widely applicable method for the expression and purification of functional N-terminally acetylated eukaryotic proteins.

Indexed as

AcetyltransferasesBiochemistryCarrier ProteinsCell Cycle ProteinsEscherichia coliHumansIntracellular Signaling Peptides and ProteinsProtein BindingProtein Processing, Post-TranslationalProteinsProtein Structure, TertiaryRecombinant ProteinsSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSchizosaccharomycesSchizosaccharomyces pombe ProteinsAcetyltransferasesCarrier ProteinsCdc8 protein, S pombeCell Cycle ProteinsIntracellular Signaling Peptides and ProteinsNatB protein, S cerevisiaeProteinsRecombinant ProteinsSaccharomyces cerevisiae ProteinsSchizosaccharomyces pombe ProteinsSPART protein, humanTfs1 protein, S cerevisiaeTropomyosin

Identifiers

PMID21203426
PMCPMC3009751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.